Napredna pretraga

Pregled bibliografske jedinice broj: 597640

First- and second-trimester prenatal screening of fetal aneuploidies in Croatia: Our experience in conformity with clinical practice and pregnant women's attitudes


Tišlarić-Medenjak, Dubravka; Zec, Ivana
First- and second-trimester prenatal screening of fetal aneuploidies in Croatia: Our experience in conformity with clinical practice and pregnant women's attitudes // Clinical Chemistry and Laboratory Medicine / Mario Plebani (ur.).
Berlin, Germany: DE GRUYTER, 2012. str. A186-A187 (predavanje, međunarodna recenzija, sažetak, stručni)


Naslov
First- and second-trimester prenatal screening of fetal aneuploidies in Croatia: Our experience in conformity with clinical practice and pregnant women's attitudes

Autori
Tišlarić-Medenjak, Dubravka ; Zec, Ivana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Clinical Chemistry and Laboratory Medicine / Mario Plebani - Berlin, Germany : DE GRUYTER, 2012, A186-A187

Skup
4th Slovenian Congress of Clinical Chemistry with international participation and 20th International Symposium of the Slovenian Association for Clinical Chemistry and Croatian Society of Medical Biochemists

Mjesto i datum
Portorož, Slovenia, 28-29.09.2012

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
First- and second- trimester prenatal screening; Down syndrome

Sažetak
We present the results of a single Laboratory, in which the first- and second-trimester screening of fetal aneuploidies has been available. Second trimester biochemical screening, using maternal serum alpha-fetoprotein (MS-AFP) and free β-subunit of human chorionic gonadotropin (free β-hCG) has been performed from November 1996. Our previous study illustrated the first 10-years' of second-trimester screening performance in a population of 11, 292 of pregnant women, with mean maternal age at term 31.6+/-4.8 years. Detection rate (DR) for trisomy 21 was 75% (21/28), with an overall false positive rate (FPR) of 10.8%. DR of trisomy 18 was 50% (2/4). On the basis of cut-off MS-AFP MoM≥2.5, 11 cases of neural tube and ventral wall defects were detected. In addition, in pregnant women under risk ≥1:250, we found 20 cases with other chromosomal anomalies. In the year 2006, first-trimester screening, combining nuchal translucency (NT), pregnancy associated plasma protein-A (PAPP-A) and free β-hCG, was introduced as a part of routine antenatal care. Till the end of 2011, combined test was performed in 10, 760 of pregnant women, with mean age of 31.9+/-4.5 years at sampling date. Using the combined risk 1:300 as cut-off value, estimated FPR for the whole population was 4.1%. DR for trisomy 21 was 86.9% (20/23) and 92.3% for trisomies 18+13 (12/13). By now, a total of 19 gynecologists attended a training course for the first-trimester ultrasound screening, organized under auspices of the Fetal Medicine Foundation ; three of them achieved the certificate of competence for measurement of NT, nasal bone (NB), fronto-maxillary facial angle, ductus venosus flow and tricuspid regurgitation. In Croatia, the Croatian Institute for Health Insurance has covered the costs referring second-trimester biochemical screening for all women, while the combined tests are performed on women’s own expense. Although the pregnancy care system differs within particular Croatian regions, there is a progressive trend in number of women undergoing first-trimester combined screening. The survey conducted in Croatian pregnant women showed that the majority of women (73%) would prefer the first-trimester combined screening test over the second-trimester biochemical screening. We also showed that the age, level of education and previous knowledge were significant variables predictive for the choice of the test.

Izvorni jezik
Engleski



POVEZANOST RADA


Autor s matičnim brojem:
Dubravka Tišlarić-Medenjak, (65684)